Ibandronate sodium monohydrate
- Product Name
- Ibandronate sodium monohydrate
- CAS No.
- 138926-19-9
- Chemical Name
- Ibandronate sodium monohydrate
- Synonyms
- Boniva;Bonviva;Ibandrate;BM-21.0955;RPR-102289A;Ibronate Sodium;Ibadronate SodiuM;Ibandronate sodium;Boniva monohydrate;Bondronat monohydrate
- CBNumber
- CB4286017
- Molecular Formula
- C9H24NNaO8P2
- Formula Weight
- 359.23
- MOL File
- 138926-19-9.mol
Ibandronate sodium monohydrate Property
- Melting point:
- 840C (dec)
- storage temp.
- Keep in dark place,Inert atmosphere,2-8°C
- solubility
- Soluble in DMSO (up to at least 25 mg/ml)
- form
- solid
- color
- White
- Stability:
- Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.
- CAS DataBase Reference
- 138926-19-9(CAS DataBase Reference)
Safety
- Hazard Codes
- Xn
- Risk Statements
- 40
- Safety Statements
- 22-36-24/25
- HS Code
- 29319090
Hazard and Precautionary Statements (GHS)
- Symbol(GHS)
-
- Signal word
- Warning
- Hazard statements
-
H302Harmful if swallowed
H315Causes skin irritation
H319Causes serious eye irritation
H335May cause respiratory irritation
- Precautionary statements
-
P261Avoid breathing dust/fume/gas/mist/vapours/spray.
P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.
N-Bromosuccinimide Price
- Product number
- 21361
- Product name
- Ibandronate (sodium hydrate)
- Purity
- ≥95%
- Packaging
- 25mg
- Price
- $40
- Updated
- 2024/03/01
- Product number
- 21361
- Product name
- Ibandronate (sodium hydrate)
- Purity
- ≥95%
- Packaging
- 50mg
- Price
- $76
- Updated
- 2024/03/01
- Product number
- 21361
- Product name
- Ibandronate (sodium hydrate)
- Purity
- ≥95%
- Packaging
- 100mg
- Price
- $141
- Updated
- 2024/03/01
- Product number
- 21361
- Product name
- Ibandronate (sodium hydrate)
- Purity
- ≥95%
- Packaging
- 250mg
- Price
- $312
- Updated
- 2024/03/01
- Product number
- 280375
- Product name
- Ibandronate sodium monohydrate
- Packaging
- 5g
- Price
- $337
- Updated
- 2021/12/16
Ibandronate sodium monohydrate Chemical Properties,Usage,Production
Description
Ibandronate Sodium Monohydrate is a highly potent nitrogen-containing bisphosphonate used for the treatment of osteoporosis.
Ibandronate Sodium Monohydrate inhibits bone resorption as a sodium salt and complexed with technetium Tc 99m for bone imaging. The monophosphonates are not active and the biphosphonates are used in disorders affecting the skeleton such as metastatic disease, asteoporosis and Paget's. Ibandronate Sodium Monohydrate is an inhibitor of FDPS.
Chemical Properties
[1-Hydroxy-3-(methylpentylamino)-propylidene]bisphosphonic acid sodium salt is White Crystalline Powder
Uses
Inhibits bone resorption as a sodium salt and complexed with technetium Tc 99m for bone imaging. The monophosphonates are not active. Biphosphonates are used in disorders affecting the skeleton such as asteoporosis, metastatic disease, and Paget d
Uses
bone resorption inhibitor, anthypercalcemic
Uses
An inhibitor of bone resorption
Mechanism of action
The action of ibandronate on bone tissue is based on its affinity for hydroxyapatite, which is part of the mineral matrix of bone. Ibandronate inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women, it reduces the elevated rate of bone turnover, leading to, on average, a net gain in bone mass.
Pharmacokinetics
Absorption
The absorption of oral ibandronate occurs in the upper gastrointestinal tract. Plasma concentrations increase in a dose-linear manner up to 50 mg oral intake and increases nonlinearly above this dose.
Following oral dosing, the time to maximum observed plasma ibandronate concentrations ranged from 0.5 to 2 hours (median 1 hour) in fasted healthy postmenopausal women. The mean oral bioavailability of 2.5 mg ibandronate was about 0.6% compared to intravenous dosing. The extent of absorption is impaired by food or beverages (other than plain water). The oral bioavailability of ibandronate is reduced by about 90% when BONIVA is administered concomitantly with a standard breakfast in comparison with bioavailability observed in fasted subjects. There is no meaningful reduction in bioavailability when ibandronate is taken at least 60 minutes before a meal. However, both bioavailability and the effect on bone mineral density (BMD) are reduced when food or beverages are taken less than 60 minutes following an ibandronate dose.
Distribution
After absorption, ibandronate either rapidly binds to bone or is excreted into urine. In humans, the apparent terminal volume of distribution is at least 90 L, and the amount of dose removed from the circulation via the bone is estimated to be 40% to 50% of the circulating dose. In vitro protein binding in human serum was 99.5% to 90.9% over an ibandronate concentration range of 2 to 10 ng/mL in one study and approximately 85.7% over a concentration range of 0.5 to 10 ng/mL in another study.
Metabolism
There is no evidence that ibandronate is metabolized in humans.
https://www.accessdata.fda.gov
References
1) Russell (2006), Ibandronate: Pharmacology and preclinical studies; Bone 38 S7
Ibandronate sodium monohydrate Preparation Products And Raw materials
Raw materials
Preparation Products
Ibandronate sodium monohydrate Suppliers
- Tel
- --
- Fax
- --
- info@gensenta.com.tr
- Country
- Turkey
- ProdList
- 4
- Advantage
- 58
View Lastest Price from Ibandronate sodium monohydrate manufacturers
- Product
- Ibandronate sodium monohydrate 138926-19-9
- Price
- US $0.00/Kg/Bag
- Min. Order
- 1KG
- Purity
- 98%-102%
- Supply Ability
- 100kg
- Release date
- 2021-09-17
- Product
- Ibandronate Sodium 138926-19-9
- Price
- US $0.00/g
- Min. Order
- 1g
- Purity
- More Than 99%
- Supply Ability
- 100kg/Month
- Release date
- 2024-09-19
- Product
- Ibandronate Sodium 138926-19-9
- Price
- US $1.00-0.00/KG
- Min. Order
- 1KG
- Purity
- 99%
- Supply Ability
- 20 tons
- Release date
- 2020-01-16